TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/24/2026

1. INTC
2. DECK
3. META
4. AMD
5. INFY
6. RNG
7. SPY
8. UNP
9. GOOGL
10. DGX

Go back to TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
TG THERAP (NASDAQ: TGTX) Delayed: 56.04 +0.54 (0.97%)
Previous Close $55.50    52 Week High $14.87 
Open $56.01    52 Week Low $4.90 
Day High $56.45    P/E N/A 
Day Low $53.86    EPS $-0.67 
Volume 1,429,823